This company is developing treatments that prevent cancer cells self-repairing, based on a process called DNA damage response. These therapies kill some cancer cells and make others easier to eliminate with radiotherapy and chemotherapy. It was founded in 2016 as a spinout from Cancer Research UK’s Commercial Partnerships team, and launched by chief executive Niall Martin, 56, and chief scientific officer Graeme Smith, 51. It collaborates with leading DNA repair researchers worldwide, such as The Institute of Cancer Research London and the Netherlands Cancer Institute, and is based in the Babraham Research Campus in Cambridge. The firm has raised $122m including an $86m funding round in August 2018, which included investors Pfizer, Life Science Partners, and Novartis.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.